Company

Medexus Pharmaceuticals, Inc.

Headquarters: Bolton, ON, Canada

CEO: Mr. Kenneth d'Entremont

TSX: MDP +4.08%

Market Cap

C$54.1 Million

CAD as of July 1, 2024

US$39.4 Million

Market Cap History

Medexus Pharmaceuticals, Inc. market capitalization over time

Evolution of Medexus Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Medexus Pharmaceuticals, Inc.

Detailed Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis psoriasis, and juvenile idiopathic arthritis; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also include Treosulfan, a conditioning agent used prior to stem cell transplantation; and Triamcinolone Hexacetonide for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Bolton, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Medexus Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: TSX: MDP wb_incandescent

Stock: FSX: P731 wb_incandescent

Stock: OTC: MEDXF wb_incandescent

Details

Headquarters:

35 Nixon Road

Unit 1

Bolton, ON L7E 1K1

Canada